252 related articles for article (PubMed ID: 23724067)
21. Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro.
Lutz L; Fitzner IC; Ahrens T; Geißler AL; Makowiec F; Hopt UT; Bogatyreva L; Hauschke D; Werner M; Lassmann S
Am J Cancer Res; 2016; 6(3):664-76. PubMed ID: 27152243
[TBL] [Abstract][Full Text] [Related]
22. Disruption of Planar Cell Polarity Pathway Attributable to Valproic Acid-Induced Congenital Heart Disease through Hdac3 Participation in Mice.
Duan HY; Zhou KY; Wang T; Zhang Y; Li YF; Hua YM; Wang C
Chin Med J (Engl); 2018 Sep; 131(17):2080-2088. PubMed ID: 30127218
[TBL] [Abstract][Full Text] [Related]
23. Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3.
Pufahl L; Katryniok C; Schnur N; Sorg BL; Metzner J; Grez M; Steinhilber D
J Cell Mol Med; 2012 Jul; 16(7):1461-73. PubMed ID: 21883892
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Wilson AJ; Byun DS; Popova N; Murray LB; L'Italien K; Sowa Y; Arango D; Velcich A; Augenlicht LH; Mariadason JM
J Biol Chem; 2006 May; 281(19):13548-13558. PubMed ID: 16533812
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylases are required for amphibian tail and limb regeneration but not development.
Taylor AJ; Beck CW
Mech Dev; 2012; 129(9-12):208-18. PubMed ID: 22947425
[TBL] [Abstract][Full Text] [Related]
26. Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression.
Larsson P; Ulfhammer E; Magnusson M; Bergh N; Lunke S; El-Osta A; Medcalf RL; Svensson PA; Karlsson L; Jern S
PLoS One; 2012; 7(2):e31573. PubMed ID: 22363677
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms.
Sinha P; Cree SL; Miller AL; Pearson JF; Kennedy MA
Pharmacogenomics J; 2021 Jun; 21(3):359-375. PubMed ID: 33649518
[TBL] [Abstract][Full Text] [Related]
28. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
30. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells.
Sharda A; Rashid M; Shah SG; Sharma AK; Singh SR; Gera P; Chilkapati MK; Gupta S
Clin Epigenetics; 2020 Jan; 12(1):4. PubMed ID: 31900196
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children.
Lundh M; Christensen DP; Damgaard Nielsen M; Richardson SJ; Dahllöf MS; Skovgaard T; Berthelsen J; Dinarello CA; Stevenazzi A; Mascagni P; Grunnet LG; Morgan NG; Mandrup-Poulsen T
Diabetologia; 2012 Sep; 55(9):2421-31. PubMed ID: 22772764
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
33. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells.
Chou CW; Wu MS; Huang WC; Chen CC
PLoS One; 2011 Mar; 6(3):e18087. PubMed ID: 21464950
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.
Müller BM; Jana L; Kasajima A; Lehmann A; Prinzler J; Budczies J; Winzer KJ; Dietel M; Weichert W; Denkert C
BMC Cancer; 2013 Apr; 13():215. PubMed ID: 23627572
[TBL] [Abstract][Full Text] [Related]
35. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.
Göttlicher M
Ann Hematol; 2004; 83 Suppl 1():S91-2. PubMed ID: 15124690
[TBL] [Abstract][Full Text] [Related]
36. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
[TBL] [Abstract][Full Text] [Related]
38. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.
Marchion DC; Bicaku E; Turner JG; Schmitt ML; Morelli DR; Munster PN
Mol Cancer Ther; 2009 Apr; 8(4):794-801. PubMed ID: 19372552
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Li Y; Liu Y; Zhao N; Yang X; Li Y; Zhai F; Zang X; Cui W
Cell Death Dis; 2020 Sep; 11(9):753. PubMed ID: 32934224
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
